Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-28T01:04:11.750Z Has data issue: false hasContentIssue false
  • English
  • Français

Grupo de Estudios Clínicos Oncológicos del Perú (GECO PERU)

Published online by Cambridge University Press:  04 December 2006

Abstract

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Grupo de Estudios Clínicos Oncológicos del Perú (GECO PERU). Clinical trials include:

  1. Determination of prognostic factors in the outcome to a metronomic treatment with low doses of cyclophosphamide and methotrexate in patients with advanced breast cancer.

Type
Other
Information
Breast Cancer Online , Volume 9 , Supplement S1: AN OVERVIEW OF RECENT AND ONGOING CLINICAL TRIALS FOR BREAST CANCER 4th EDITION , December 2006 , pp. 168 - 171 , e58
Copyright
© 2006 Cambridge University Press

GECO PERU – Contact Details

Country

Peru

Chair

Dr C.V. Sologuren, Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos Este 2520, LIMA 34, PERU. Tel: +51 1 710 6900 Fax: +51 1 272 0309 Email:

Contact Person

Dr H. Gomez, Research Division, Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos Este 2520, LIMA 34, PERU. Tel: +51 1 710 6900 Fax: +51 1 271 1226 Email:

GECO PERU – Study Details

Title

Determination of prognostic factors in the outcome to a metronomic treatment with low doses of cyclophosphamide and methotrexate in patients with advanced breast cancer.

Coordinator(s)

Dr K. Robles, Email:

Summary

  • Most patients with advanced breast cancer have increased levels of VEGF (vascular endothelial growth factor) over those with local disease. The VEGF in the cytoplasm of the tumor cells is a predictive factor for overall survival and progression free survival.
  • M. Colleoni et al., reported a study of 64 patients with previous treatment with chemotherapy for advanced breast cancer and indicated that patients who were treated with low doses of methotrexate and cyclophosphamide showed objective responses in 19%, with overall response of 31.7%.

Scheme

Update

  • Proposed study

Related Publications

Colleoni M. Rocca A, Sandri Mt et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13:73–80.

Colleoni M, Orlando L, Sanna G et al. Metronomic low-dose oral cyclophosphamide and methotrexatte plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Annals of Oncology 2006; 17: 232–238.

MacKenzie KL, Lock RB. An endothelial metronome breast cancer? Blood 2006; 108: 407–408.

Topics

  • Metronomic chemotheraphy
  • Metastatic breast cancer

Keywords

Angiogenesis